Corcept Therapeutics Incorporated $CORT Shares Sold by Handelsbanken Fonder AB

Handelsbanken Fonder AB lowered its stake in Corcept Therapeutics Incorporated (NASDAQ:CORT) by 9.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 25,281 shares of the biotechnology company’s stock after selling 2,700 shares during the quarter. Handelsbanken Fonder AB’s holdings in Corcept Therapeutics were worth $1,856,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Catalyst Funds Management Pty Ltd bought a new stake in shares of Corcept Therapeutics during the 2nd quarter worth about $1,600,000. Ensign Peak Advisors Inc increased its stake in shares of Corcept Therapeutics by 29.3% during the second quarter. Ensign Peak Advisors Inc now owns 87,219 shares of the biotechnology company’s stock valued at $6,402,000 after acquiring an additional 19,786 shares during the period. Pinnacle Wealth Planning Services Inc. acquired a new position in shares of Corcept Therapeutics during the second quarter valued at approximately $267,000. Universal Beteiligungs und Servicegesellschaft mbH raised its holdings in Corcept Therapeutics by 291.5% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 72,601 shares of the biotechnology company’s stock worth $5,329,000 after purchasing an additional 54,059 shares in the last quarter. Finally, Cetera Investment Advisers lifted its position in Corcept Therapeutics by 32.9% in the second quarter. Cetera Investment Advisers now owns 11,129 shares of the biotechnology company’s stock worth $817,000 after purchasing an additional 2,755 shares during the period. Institutional investors own 93.61% of the company’s stock.

Insider Transactions at Corcept Therapeutics

In other Corcept Therapeutics news, insider William Guyer sold 20,000 shares of Corcept Therapeutics stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $70.49, for a total transaction of $1,409,800.00. Following the transaction, the insider directly owned 5,487 shares in the company, valued at approximately $386,778.63. The trade was a 78.47% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Sean Maduck sold 20,000 shares of the business’s stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $85.06, for a total transaction of $1,701,200.00. Following the sale, the insider directly owned 7,904 shares in the company, valued at approximately $672,314.24. This trade represents a 71.67% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 263,900 shares of company stock valued at $20,373,338 over the last ninety days. Corporate insiders own 20.80% of the company’s stock.

Corcept Therapeutics Stock Down 0.6%

Shares of NASDAQ CORT opened at $79.80 on Thursday. Corcept Therapeutics Incorporated has a 12 month low of $49.00 and a 12 month high of $117.33. The company has a market cap of $8.39 billion, a price-to-earnings ratio of 70.62 and a beta of 0.43. The business has a fifty day simple moving average of $78.26 and a 200-day simple moving average of $74.03.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $0.16 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.02). Corcept Therapeutics had a return on equity of 20.10% and a net margin of 18.51%.The company had revenue of $207.64 million during the quarter, compared to analysts’ expectations of $223.78 million. During the same period in the prior year, the business posted $0.41 EPS. The company’s revenue for the quarter was up 13.8% compared to the same quarter last year. Corcept Therapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Corcept Therapeutics Incorporated will post 1.36 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Canaccord Genuity Group reiterated a “buy” rating and set a $140.00 price target on shares of Corcept Therapeutics in a research report on Thursday, September 25th. Wall Street Zen cut Corcept Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, October 18th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Corcept Therapeutics in a report on Wednesday, November 19th. HC Wainwright reiterated a “buy” rating and issued a $145.00 price target on shares of Corcept Therapeutics in a research report on Tuesday. Finally, Wolfe Research started coverage on shares of Corcept Therapeutics in a research report on Tuesday, November 18th. They set a “peer perform” rating for the company. Four equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $135.25.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.